About Pacific Biosciences of California Inc. Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It ...
Fintel reports that on March 6, 2026, Barclays downgraded their outlook for Pacific Biosciences of California (NasdaqGS:PACB) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 79.51% ...
Pacific Biosciences of California, Inc. (PACB) has been downgraded to an Underweight rating by Barclays analyst Luke Sergott, marking a notable shift in sentiment for the biotechnology firm. With the ...
MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, announced a collaboration with DNAstack to launch the world’s first global federated dataset of HiFi whole genome sequencing ...
MENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced a collaboration with DNAstack to power the ...
The single-cell genomics industry does not stop advancing, with a steady stream of new companies, kits, acquisitions, and more. One new company, ArgenTag, was founded in Argentina during the COVID-19 ...
MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Pacific Biosciences of California Inc. (PACB) on Thursday reported a loss of $40.4 million in its fourth quarter. On a per-share basis, the Menlo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results